NEDA treatment target? No evident disease activity as an actionable outcome in practice

Natalie E. Parks; Eoin P. Flanagan; Claudia F. Lucchinetti; Dean M. Wingerchuk

doi:10.1016/j.jns.2017.10.015

NEDA treatment target? No evident disease activity as an actionable outcome in practice

Natalie E. Parks, Eoin P. Flanagan, Claudia F. Lucchinetti, Dean M. Wingerchuk

Medicine

Producción científica: Contribución a una revista › Artículo de revisión › revisión exhaustiva

26 Citas (Scopus)

Resumen

“No evident disease activity” (NEDA) is a proposed measure of disease activity-free status in multiple sclerosis (MS) that is typically defined as absence of relapses, disability progression, and MRI activity over a defined time period. NEDA is increasingly reported in randomized controlled trials of MS disease modifying therapies where it has some perceived advantages over outcomes such as annualized relapse rate. NEDA has also been proposed as a treatment goal in clinical care. At this point, the long-term implications of early NEDA remain largely unknown. We review current NEDA definitions, use in clinical trials, and its prospects for routine use as an actionable treatment target in clinical practice.

Idioma original	English
Páginas (desde-hasta)	31-34
Número de páginas	4
Publicación	Journal of the Neurological Sciences
Volumen	383
DOI	https://doi.org/10.1016/j.jns.2017.10.015
Estado	Published - dic. 15 2017

Nota bibliográfica

Funding Information:
Natalie E. Parks has provided consulting services for Biogen and Roche. Eoin P. Flanagan reports no disclosures. Claudia F. Lucchinetti shares in royalties from marketing of kits for detecting AQP4 autoantibody, reports research grants from Sanofi, Novartis, and Biogen Pharmaceuticals, and receives research support from the National Multiple Sclerosis Foundation. Dean M. Wingerchuk receives research support paid to Mayo Clinic from Alexion and TerumoBCT and serves as a consultant to MedImmune.

Publisher Copyright:
© 2017 Elsevier B.V.

ASJC Scopus Subject Areas

Neurology
Clinical Neurology

PubMed: MeSH publication types

Journal Article
Review

Acceder al documento

10.1016/j.jns.2017.10.015

Otros archivos y enlaces

Citar esto

@article{adc39d35280440ef899991965e6efdf8,

title = "NEDA treatment target? No evident disease activity as an actionable outcome in practice",

abstract = "“No evident disease activity” (NEDA) is a proposed measure of disease activity-free status in multiple sclerosis (MS) that is typically defined as absence of relapses, disability progression, and MRI activity over a defined time period. NEDA is increasingly reported in randomized controlled trials of MS disease modifying therapies where it has some perceived advantages over outcomes such as annualized relapse rate. NEDA has also been proposed as a treatment goal in clinical care. At this point, the long-term implications of early NEDA remain largely unknown. We review current NEDA definitions, use in clinical trials, and its prospects for routine use as an actionable treatment target in clinical practice.",

author = "Parks, {Natalie E.} and Flanagan, {Eoin P.} and Lucchinetti, {Claudia F.} and Wingerchuk, {Dean M.}",

note = "Funding Information: Natalie E. Parks has provided consulting services for Biogen and Roche. Eoin P. Flanagan reports no disclosures. Claudia F. Lucchinetti shares in royalties from marketing of kits for detecting AQP4 autoantibody, reports research grants from Sanofi, Novartis, and Biogen Pharmaceuticals, and receives research support from the National Multiple Sclerosis Foundation. Dean M. Wingerchuk receives research support paid to Mayo Clinic from Alexion and TerumoBCT and serves as a consultant to MedImmune. Publisher Copyright: {\textcopyright} 2017 Elsevier B.V.",

year = "2017",

month = dec,

day = "15",

doi = "10.1016/j.jns.2017.10.015",

language = "English",

volume = "383",

pages = "31--34",

journal = "Journal of the Neurological Sciences",

issn = "0022-510X",

publisher = "Elsevier",

}

TY - JOUR

T1 - NEDA treatment target? No evident disease activity as an actionable outcome in practice

AU - Parks, Natalie E.

AU - Flanagan, Eoin P.

AU - Lucchinetti, Claudia F.

AU - Wingerchuk, Dean M.

N1 - Funding Information: Natalie E. Parks has provided consulting services for Biogen and Roche. Eoin P. Flanagan reports no disclosures. Claudia F. Lucchinetti shares in royalties from marketing of kits for detecting AQP4 autoantibody, reports research grants from Sanofi, Novartis, and Biogen Pharmaceuticals, and receives research support from the National Multiple Sclerosis Foundation. Dean M. Wingerchuk receives research support paid to Mayo Clinic from Alexion and TerumoBCT and serves as a consultant to MedImmune. Publisher Copyright: © 2017 Elsevier B.V.

PY - 2017/12/15

Y1 - 2017/12/15

N2 - “No evident disease activity” (NEDA) is a proposed measure of disease activity-free status in multiple sclerosis (MS) that is typically defined as absence of relapses, disability progression, and MRI activity over a defined time period. NEDA is increasingly reported in randomized controlled trials of MS disease modifying therapies where it has some perceived advantages over outcomes such as annualized relapse rate. NEDA has also been proposed as a treatment goal in clinical care. At this point, the long-term implications of early NEDA remain largely unknown. We review current NEDA definitions, use in clinical trials, and its prospects for routine use as an actionable treatment target in clinical practice.

AB - “No evident disease activity” (NEDA) is a proposed measure of disease activity-free status in multiple sclerosis (MS) that is typically defined as absence of relapses, disability progression, and MRI activity over a defined time period. NEDA is increasingly reported in randomized controlled trials of MS disease modifying therapies where it has some perceived advantages over outcomes such as annualized relapse rate. NEDA has also been proposed as a treatment goal in clinical care. At this point, the long-term implications of early NEDA remain largely unknown. We review current NEDA definitions, use in clinical trials, and its prospects for routine use as an actionable treatment target in clinical practice.

UR - http://www.scopus.com/inward/record.url?scp=85042648307&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85042648307&partnerID=8YFLogxK

U2 - 10.1016/j.jns.2017.10.015

DO - 10.1016/j.jns.2017.10.015

M3 - Review article

C2 - 29246616

AN - SCOPUS:85042648307

SN - 0022-510X

VL - 383

SP - 31

EP - 34

JO - Journal of the Neurological Sciences

JF - Journal of the Neurological Sciences

ER -

NEDA treatment target? No evident disease activity as an actionable outcome in practice

Resumen

Nota bibliográfica

ASJC Scopus Subject Areas

PubMed: MeSH publication types

Acceder al documento

Otros archivos y enlaces

Huella

Citar esto